TREVENA INC (TRVN) Stock News

Trevena Reports Third Quarter 2024 Results and Provides Business Update

CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...

12 Health Care Stocks Moving In Monday's After-Market Session

Mentions: SNGX RNA OGEN CUE ...

Dow Tumbles Over 400 Points; Duckhorn Portfolio Shares Surge

Mentions: UVE AZN ALTM HRTG ...

Trevena Announces Reverse Stock Split

CHESTERBROOK, Pa., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...

TRVN Stock Earnings: Trevena Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Trevena (NASDAQ:TRVN) just reported results for the second quarter of 2024.Trev...

TRVN Stock Earnings: Trevena Beats EPS for Q2 2024

TRVN stock results show that Trevena beat analyst estimates for earnings per share the second quarter of 2024.

Trevena Announces Receipt of Nasdaq Delisting Notification

CHESTERBROOK, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and...

TRVN Stock Earnings: Trevena Beats EPS for Q1 2024

TRVN stock results show that Trevena beat analyst estimates for earnings per share the first quarter of 2024.

Trevena Reports Second Quarter 2024 Results and Provides Business Update

TRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neuropathic pain and epilepsy, demonstrated sustained long-term...

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Mentions: SGMT BRNS RCUS ZURA ...

Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing

Trevena expects to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINVYK US partnering and...

Trevena Announces Preclinical TRV045 Data Providing Insight Into Novel Mechanism of Analgesic Effect in Chronic Neuropathic Pain Model and Demonstrating Statistically Significant Anti-Seizure Activity in Epilepsy Models

TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization ...

Trevena Reports First Quarter 2024 Results and Provides Business Update

TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile Ongoing clinical PK study...

Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update

TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies Company...

Trevena files to sell 2.78M shares for holders (NASDAQ:TRVN)

Trevena (TRVN) files prospectus for the resale of 2.78M shares of common stock by selling stockholders.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Pre-market stock movers are worth checking out on Tuesday to catch up on all of the hottest stock market news for this morning!

Mentions: SNTG ELTX SYRA ZJYL ...